Phenotypic approach to personalization of pharmacotherapy in patients with congenetive heart failure with low left ventricular ejection fraction
https://doi.org/10.21626/vestnik/2023-2/04
EDN: WVYFGD
References
1. Groenewegen A., Rutten F.H., Mosterd A., Hoes A.W. Epidemiology of heart failure. Eur. J Heart Fail. 2020;22(8):1342-1356. DOI: 10.1002/ejhf.1858.
2. Polyakov D.S., Fomin I.V., Belenkov Yu.N., Mareyev V.Yu., Ageyev F.T., Artem’yeva E.G., Artem’yeva E.G., Badin Yu.V., et al. Chronic heart failure in the Russian Federation: what has changed over 20 years of follow-up? Results of the EPOCH-CHF study. Kardiologiya. 2021;61(4):4-14 (in Russ.). DOI: 10.18087/cardio.2021.4.n1628. EDN: WSZNFS.
3. Savarese G., Becher P.M., Lund L.H., Seferovic P., Rosano G.M.C., Coats A.J.S. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovascular Research. 2023;118(17): 3272-3287. DOI: 10.1093/cvr/cvac013.
4. Shlyakhto E.V., Zvartau N.E., Villevalde S.V., Yakovlev A.N., Soloveva A.E., Avdonina N.G., Medvedeva E.A., Endubaeva G.V., et al. Implemented models and elements for heart failure care in the regions of the Russian Federation: prospects for transformation into regional cardiovascular risk management systems.Russian Journal of Cardiology. 2020;25(4):10-18 (in Russ.). DOI: 10.15829/1560-4071-2020-4-3792. EDN: EGQYDD.
5. Heidenreich P.A., Bozkurt B., Aguilar D., Allen L.A., Byun J.J., Colvin M.M., Deswal A., Drazner M.H., et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895-1032. DOI: 10.1161/CIR.0000000000001063.
6. McDonagh T.A., Metra M., Adamo M., Gardner R.S., Baumbach A., Böhm M., Burri H., Butler J., et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2021;42(36):3599-3726. DOI: 10.1093/eurheartj/ehab368.
7. Tereshchenko S.N., Galyavich A.S., Uskach T.M., Ageyev F.T., Arutyunov G.P., Begrambekova Yu.L., Belenkov Yu.N., Boytsov S.A., et al. 2020 Clinical practice guidelines for Chronic heart failure.Russian Journal of Cardiology. 2020;25(11):311-374 (in Russ.). DOI: 10.15829/1560-4071-2020-4083. EDN: LJGGQV
8. Rosano G.M.C., Moura B., Metra M., Böhm M., Bauersachs J., Ben Gal T., Adamopoulos S., Abdelhamid M., et al. Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. Eur. J Heart Fail. 2021;23(6): 872-881DOI:10.1002/ejhf.2206.
9. Polunina E.A., Voronina L.P., Popov E.A., Belyakova I.S., Polunina O.S., Tarasochkina D.S. Prognostic algorithms for the progression of chronic heart failure depending on the clinical phenotype. Cardiovascular therapy and prevention. 2019;18(3):41-47 (in Russ.). DOI: 10.15829/1728-8800-2019-3-41-47. EDN: MGSNAC.
10. Rosano G.M.C., Allen L.A., Abdin A., Lindenfeld J., O’Meara E. Drug Layering in Heart Failure: Phenotype-Guided Initiation. J Am Coll Cardiol HF. 2021;9(11):775-783. DOI: 10.1016/j.jchf.2021.06.011.
11. Nadar S.K., Shaikh M.M. Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev. 2019;5(1):50-56. DOI:10.15420/cfr.2018.27.2.
12. Egerstedt A., Berntsson J., Smith M.L., Gidlöf O., Nilsson R., Benson M., Wells Q.S., Celik S., et al. Profiling of the plasma proteome across different stages of human heart failure. Nature Сommunications. 2019;10(1):1-13. DOI: 10.1038/s41467-019-13306-y
13. Aliyeva A.M., Pinchuk T.V., Almazova I.I., Ettinger O.A., Valiyev R.K., Batov M.A., Nikitin I.G. Clinical significance of determining the ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-526 (in Russ.). DOI: 10.26442/20751753.2021.6.200606. EDN: ZWUXUD.
14. Osipova O.A., Nagibina A.I., Komisov A.A., Petrova G.D., Shekhovtsova L.V., Vlasenko M.A., Vlasenko O.A. Pathomorphological mechanisms for regulation of myocardial fibrosis formation in patients with chronic heart failure with underlying ischemic heart disease. Zhurnal serdechnaya nedostatochnost’. 2016;17(5(98)):357-364 (in Russ.). DOI: 10.18087/RHFJ.2016.5.2137. EDN: XIMIXF.
15. Drapkina O.M., Shepel R.N., Deeva T.A. Prognostic significance of galectin-3 level assessment in metabolic syndrome patients with heart failure. Cardiovascular therapy and prevention. 2017;16(6):82-86 (in Russ.). DOI: 10.15829/1728-8800-2017-6-82-86. EDN: ZVZZIP.
16. Martynovich T.V., Akimova N.S., Fedotov E.A., Shvarts Yu.G. Gene polymorphism in association with atherosclerosis development and cognition disorders in patients with ischemic chronic heart failure. Cardiovascular therapy and prevention. 2015;14(1):30-34 (in Russ.). DOI: 10.15829/1728-8800-2015-1-30-34. EDN: TLAOWD.
17. De Keulenaer G.W., Brutsaert D.L. The heart failure spectrum: time for a phenotype-oriented approach. Circulation. 2009;119(24):3044-3046. DOI: 10.1161/CIRCULATIONAHA.109.870006.
18. González A., Richards A.M., de Boer R.A., Thum T., Arfsten H., Hülsmann M., Falcao-Pires I., Díez J., et al. Cardiac remodelling - Part 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2022;24(8):927-943 DOI: 10.1002/ejhf.2493.
19. Swedberg K., Komajda M., Bohm M., Borer J.S., Ford I., Dubost-Brama A., Lerebours G., Tavazzi L., et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376(9744):875-885. DOI: 10.1016/S0140-6736(10)61198-1.
20. Kotecha D., Holmes J., Krum H., Altman D.G., Manzano L., Cleland J.G., Lip G.Y., Coats A.J., et al. Efficacy of β blockers in patients with heart failure plus atrial fibrillation: an individual-patient data meta-analysis. Lancet. 2014;384(9961):2235-2243. DOI: 10.1016/S0140-6736(14)61373-8.
21. Cleland J.G., Bunting K.V., Flather M.D., Altman D.G., Holmes J., Coats A.J.S., Manzano L., McMurray J.J., et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018;39(1):26-35. DOI: 10.1093/eurheartj/ehx564.
22. Chioncel O., Mebazaa A., Maggioni A.P., Harjola V.P., Rosano G., Laroche C., Piepoli M.F., Crespo-Leiro M.G., et al. Acute heart failure congestion and perfusion status - impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. Eur J Heart Fail. 2019;21(11):1338-1352. DOI: 10.1002/ejhf.1492.
23. Beltrami M., Milli M., Dei L.L., Palazzuoli A. The Treatment of Heart Failure in Patients with Chronic Kidney Disease: Doubts and New Developments from the Last ESC Guidelines. J. Clin. Med. 2022;11(8):2243. DOI: 10.3390/jcm11082243
24. Beldhuis I.E., Lam C.S.P., Testani J.M., Voors A.A., Van Spall H.G.C., ter Maaten J.M., Damman K. Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease. Circulation. 2022;145(9):693-712. DOI: 10.1161/CIRCULATIONAHA.121.052792.
25. Mullens W., Martens P., Testani J.M., Tang W.H.W., Skouri H., Verbrugge F.H., Fudim M., Iacoviello M., et al. Renal effects of guideline-directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2022;24(4):603-619. DOI:10.1002/ejhf.2471.
Review
For citations:
Povetkin S.V. Phenotypic approach to personalization of pharmacotherapy in patients with congenetive heart failure with low left ventricular ejection fraction. Humans and their health. 2023;26(2):31-39. (In Russ.) https://doi.org/10.21626/vestnik/2023-2/04. EDN: WVYFGD
Views:
290
Email this article 